Back to Search Start Over

Pretreatment Hemoglobin Levels and Platelet-to-Lymphocyte Ratio Predict Survival Benefit from Pembrolizumab in Advanced Urothelial Carcinoma

Authors :
RYO KURASHINA
KIYOHIRO ANDO
MASAHARU INOUE
RIKO MARUYAMA
KOUKI MITANI
HISANORI TAKENOBU
MASAYUKI HARUTA
RITSUKO ONUKI
YOH MATSUOKA
TAKEHIKO KAMIJO
YUKIO KAGEYAMA
Source :
Cancer Diagn Progn
Publication Year :
2023
Publisher :
International Institute of Anticancer Research, 2023.

Abstract

Background/Aim: Several prognostic risk factors have been recognized when using cisplatin-based conventional chemotherapy for the treatment of advanced urothelial carcinoma (UC); these include performance status (PS), liver metastasis, hemoglobin (Hb) levels, time from prior chemotherapy (TFPC), and other systemic inflammation scores including neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR). However, the benefit of these indicators for predicting outcome of immune checkpoint inhibitors is not fully understood. Here, we investigated the predictive value of the indicators in patients who received pembrolizumab for the treatment of advanced UC. Patients and Methods: Seventy-five patients who received pembrolizumab treatment for advanced UC were included. The Karnofsky PS, liver metastasis, hemoglobin levels, TFPC, NLR, and PLR were analyzed, and their relationship with overall survival (OS) was determined. Results: All factors were highlighted as significant prognostic indicators for OS in the univariate proportional regression analysis (p

Subjects

Subjects :
Research Article

Details

Language :
English
Database :
OpenAIRE
Journal :
Cancer Diagn Progn
Accession number :
edsair.doi.dedup.....27411fffa7564e7d7081b56cd1d3ca2f